CCR News Update

COVID-19 is an emerging, rapidly evolving situation. What people with cancer should know: https://www.cancer.gov/coronavirus. Get the latest public health information from CDC: https://www.coronavirus.gov. Get the latest research information from NIH: https://www.nih.gov/coronavirus. Center for Cancer Research News Read more about our latest scientific discoveries, clinical trials and faculty news from the NCI Center for Cancer Research.   Phase 1 CAR T-cell therapy leads to years-long remissions in relapsed B-cell lymphoma patients   In a Journal of Clinical Oncology article, results of a phase 1 trial by CCR investigators show that CAR T-cell therapy can result in long-lasting remissions in patients with certain relapsed B-cell lymphomas. Many who had life expectancies of only six months or less during the clinical trial of the therapy, which spanned from 2009 to 2015, remain in complete remission. Clinical trial tests immunotherapy combination for advanced HPV-associated cancers   Human papillomavirus (HPV) is the most common sexually transmitted infection. More than 30,000 cases of HPV+ cancers occur every year in the United States. CCR investigators are leading a study using a combination of 3 immunotherapy drugs to treat HPV+ cancers. Clinical trial tests vaccine for late-stage HPV-linked tumors   The human papillomavirus (HPV) has been linked to many kinds of cancer, including cervical, uterine, vaginal, penile and oropharyngeal. For those who develop advanced HPV-linked cancer, the NIH Clinical Center has a clinical trial open to test a vaccine with and without checkpoint inhibitors to see if this treatment approach can stop tumor growth. You are subscribed to CCR News from the National Cancer Institute. Read the latest news about our scientific discoveries, new clinical trials and other events happening at the Center for Cancer Research. Having trouble viewing this email? View it as a Web page. follow us on Twitter! • Current CCR Career Opportunities Center for Cancer Research • National Cancer Institute • National Institutes of Health Subscriber services: manage subscriptions • help     This email was sent to edwardlorilla1986.paxforex@blogger.com using GovDelivery Communications Cloud on behalf of: National Cancer Institute · BG 9609 MSC 9760 · 9609 Medical Center Drive · Bethesda, MD 20892